886 related articles for article (PubMed ID: 30848932)
1. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
2. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
3. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling.
Alrob OA; Sankaralingam S; Ma C; Wagg CS; Fillmore N; Jaswal JS; Sack MN; Lehner R; Gupta MP; Michelakis ED; Padwal RS; Johnstone DE; Sharma AM; Lopaschuk GD
Cardiovasc Res; 2014 Sep; 103(4):485-97. PubMed ID: 24966184
[TBL] [Abstract][Full Text] [Related]
4. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
5. Theacrine protects against nonalcoholic fatty liver disease by regulating acylcarnitine metabolism.
Wang GE; Li YF; Zhai YJ; Gong L; Tian JY; Hong M; Yao N; Wu YP; Kurihara H; He RR
Metabolism; 2018 Aug; 85():227-239. PubMed ID: 29727630
[TBL] [Abstract][Full Text] [Related]
6. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
7. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.
Zeng X; Yang J; Hu O; Huang J; Ran L; Chen M; Zhang Y; Zhou X; Zhu J; Zhang Q; Yi L; Mi M
Antioxid Redox Signal; 2019 Jan; 30(2):163-183. PubMed ID: 29310441
[No Abstract] [Full Text] [Related]
8. Sirtuin 3-mediated deacetylation of acyl-CoA synthetase family member 3 by protocatechuic acid attenuates non-alcoholic fatty liver disease.
Sun R; Kang X; Zhao Y; Wang Z; Wang R; Fu R; Li Y; Hu Y; Wang Z; Shan W; Zhou J; Tian X; Yao J
Br J Pharmacol; 2020 Sep; 177(18):4166-4180. PubMed ID: 32520409
[TBL] [Abstract][Full Text] [Related]
9. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.
Hirschey MD; Shimazu T; Goetzman E; Jing E; Schwer B; Lombard DB; Grueter CA; Harris C; Biddinger S; Ilkayeva OR; Stevens RD; Li Y; Saha AK; Ruderman NB; Bain JR; Newgard CB; Farese RV; Alt FW; Kahn CR; Verdin E
Nature; 2010 Mar; 464(7285):121-5. PubMed ID: 20203611
[TBL] [Abstract][Full Text] [Related]
10. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation.
Teodoro JS; Duarte FV; Gomes AP; Varela AT; Peixoto FM; Rolo AP; Palmeira CM
Mitochondrion; 2013 Nov; 13(6):637-46. PubMed ID: 24041461
[TBL] [Abstract][Full Text] [Related]
11. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site.
Bharathi SS; Zhang Y; Mohsen AW; Uppala R; Balasubramani M; Schreiber E; Uechi G; Beck ME; Rardin MJ; Vockley J; Verdin E; Gibson BW; Hirschey MD; Goetzman ES
J Biol Chem; 2013 Nov; 288(47):33837-33847. PubMed ID: 24121500
[TBL] [Abstract][Full Text] [Related]
12. Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice.
Nassir F; Arndt JJ; Johnson SA; Ibdah JA
J Lipid Res; 2018 Jun; 59(6):967-973. PubMed ID: 29581157
[TBL] [Abstract][Full Text] [Related]
13. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
Wang Y; Tai YL; Zhao D; Zhang Y; Yan J; Kakiyama G; Wang X; Gurley EC; Liu J; Liu J; Liu J; Lai G; Hylemon PB; Pandak WM; Chen W; Zhou H
Cells; 2021 Jan; 10(2):. PubMed ID: 33494295
[TBL] [Abstract][Full Text] [Related]
14. Chronic High Fat Diet Intake Impairs Hepatic Metabolic Parameters in Ovariectomized Sirt3 KO Mice.
Pinterić M; Podgorski II; Popović Hadžija M; Tartaro Bujak I; Tadijan A; Balog T; Sobočanec S
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924115
[TBL] [Abstract][Full Text] [Related]
15. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.
Weng SW; Wu JC; Shen FC; Chang YH; Su YJ; Lian WS; Tai MH; Su CH; Chuang JH; Lin TK; Liou CW; Chu TH; Kao YH; Wang FS; Wang PW
Diabetologia; 2023 May; 66(5):913-930. PubMed ID: 36692509
[TBL] [Abstract][Full Text] [Related]
16. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.
Guo T; Woo SL; Guo X; Li H; Zheng J; Botchlett R; Liu M; Pei Y; Xu H; Cai Y; Zeng T; Chen L; Li X; Li Q; Xiao X; Huo Y; Wu C
Sci Rep; 2016 Mar; 6():22612. PubMed ID: 26936230
[TBL] [Abstract][Full Text] [Related]
17. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
[TBL] [Abstract][Full Text] [Related]
18. Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1.
Li A; Liu Q; Li Q; Liu B; Yang Y; Zhang N
EBioMedicine; 2018 Aug; 34():243-255. PubMed ID: 30093307
[TBL] [Abstract][Full Text] [Related]
19. Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD.
Chen T; Liu J; Li N; Wang S; Liu H; Li J; Zhang Y; Bu P
PLoS One; 2015; 10(3):e0118909. PubMed ID: 25748450
[TBL] [Abstract][Full Text] [Related]
20. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
